Table 2.
Laboratory studies on the role of bFGF in cutaneous wound management and scar prevention
| Title | Type of study | Method | Number of subjects | Results |
|---|---|---|---|---|
| Eto et al. [33] |
In vitro In vivo |
Evaluation of the therapeutic remodeling effects of basic fibroblast growth factor (bFGF) treatment in an animal model using human hypertrophic scar tissue implanted into nude mice | 6 | Significant decrease in scar tissue weight and collagen quantity |
| Funato et al. [34] | In vitro | Examination of the effect of bFGF on apoptosis in normal rat palatal fibroblasts and rat palatal scar fibroblasts using the TUNEL assay | 3 | bFGF induced apoptosis in myofibroblasts during palatal scar formation |
| Akasaka et al. [50] | In vitro | Investigation of the mechanisms underlying pro-apoptotic effects of bFGF on granulation tissue fibroblasts during wound healing after pretreatment with transforming growth factor (TGF)-beta1 | 5–7 | bFGF promoted apoptosis of injured tissue-derived fibroblasts pre-treated with TGF-β1 |
| Kanazawa et al. [53] | In vitro | Examination of bFGF-induced fibroblast migration in wound healing with concurrent blockade of the effect of bFGF on fibroblast proliferation by using mitomycin-C | 5 | bFGF promoted dermal fibroblast migration during the wound healing process by activating the PI3K-Rac1-JNK pathway |
| Kawai et al. [65] | In vivo | Evaluation of the effect of artificial dermis with bFGF-impregnated gelatin microspheres or bFGF in solution when implanted into full-thickness skin defects on the back of guinea pigs | 4 | Incorporation of bFGF into the artificial dermis demonstrated effectiveness by accelerating fibroblast proliferation and capillary formation in a dose-dependent manner |
| Kanda et al. [66] |
In vitro In vivo |
Application of collagen-gelatin sponge (CGS) impregnated with 7 µg/cm2 or 14 µg/cm2 of bFGF to full-thickness skin defects of normal mice and decubitus ulcers created in diabetic mice (length of the neoepithelium, and total area of newly formed capillaries in CGS were evaluated) | 36 | Artificial dermis, CGS, impregnated with 7-μg/cm2 bFGF accelerated dermis-like tissue formation 2 or 3 times earlier than artificial dermis alone |
| Kanda et al. [67] | In vitro | Evaluation of the ability of a scaffold, CGS, for sustained release of bFGF, using a pressure-induced decubitus ulcer model in genetically diabetic mice by assessment of the wound area and histological assessment of neo-epithelization | 40 | CGSs impregnated with 7–14 µg/cm2 bFGF accelerated wound healing |
| Tabata, et al. [68] |
In vitro In vivo |
Evaluation of the biological activity of controlled release of bFGF incorporated into gelatin hydrogel after subcutaneous implantation into the back of mice | 6 | Controlled release of biologically active bFGF caused by biodegradation of the acidic gelatin hydrogel induced a prolonged vascularization effect |
| Tabata et al. [69] | In vivo | In vivo release of bFGF from a biodegradable gelatin hydrogel carrier was compared with in vivo degradation of hydrogel in a diffusion chamber, and implanted in the mouse subcutis for certain periods of time | 6 | Biologically-active bFGF was released as a result of in vivo degradation of the hydrogel and induced significant neovascularization |
| Mizuno et al. [70] |
In vitro In vivo |
Examination of the stability of bFGF in a chitosan film and the therapeutic effect on wound healing in genetically diabetic mice (db/db mice) | 5 | The rate of healing was accelerated by promotion of fibroblast proliferation and granulation tissue formation |
| Matsumoto et al. [72] | Ex vivo | Histological analyses of effectiveness of bFGF-impregnated gelatin sheet in a murine model | 4 | The findings suggested that controlled release of bFGF using gelatin sheet is effective for promoting wound healing |